

## REMARKS

Applicant's attorney would like to thank the Examiner for the careful consideration given this case. The Examiner has sent a Notice of Non-Compliant Amendment under 37 CFR § 1.121 requesting that the clean and marked up copies of the claims have parenthetical expression following the claim number indicating the status of the claims as amended or newly added. Accordingly, the clean and marked up copies of the claims have been amended to include parenthetical reference to indicate the status of the claims.

In view of the remarks presented above it is believed that pending claims 1-17 are in condition for allowance and notice to such effect is respectfully requested. Should the Examiner have any questions regarding the above, the Examiner is invited to initiate a telephone conference with the undersigned.

Respectfully submitted,




Dated: March 29, 2002

By: \_\_\_\_\_

Raymond A. Miller  
Reg. No. 42,891

BENESCH, FRIEDLANDER,  
COPLAN & ARONOFF LLP  
2300 BP Tower  
200 Public Square  
Cleveland, Ohio 44114  
(216) 363-4417



VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

1. **(Amended)** A method for reducing a **pro-multiple sclerosis** (pro-MS) immune response in an individual, the method comprising administering to an individual a composition, wherein the composition comprises an affinity ligand which selectively binds to a B cell determinant, wherein the B cells targeted by the method and by the composition are nonmalignant B cells, and wherein the composition is administered in an amount effective to deplete B cells.
2. **(Amended)** The method according to claim 1, wherein the nonmalignant B cells are B cells selected from the group consisting of mature B cells and memory B cells, CD19<sup>±</sup>[+]sTn<sup>±</sup>[+] B cells, CD19<sup>±</sup>[+]CD21<sup>±</sup>[+]sTn<sup>±</sup>[+] B cells, **and** CD19<sup>±</sup>[+]CD5<sup>±</sup>[+]sTn<sup>±</sup>[+] B cells, **[and]** **or** a combination thereof.
4. **(Amended)** The method according to claim 1, wherein the composition is administered **[by a mode selected from the group consisting of]** parenterally, **[and]** **or** in a site-directed method in which the composition is delivered into an access that directly supplies central nervous tissue undergoing demyelination.
5. **(Amended)** The method according to claim 1, wherein the composition further comprises an additional component selected from the group consisting of one or more chemotherapeutic agents, an anti-inflammatory agent, a cytolytic agent, **and** a pharmaceutically acceptable carrier, **[and]** **or** a combination thereof.
6. **(Amended)** A site-directed method **[for reducing a]** for reducing a **pro-multiple sclerosis** (pro-MS) immune response in an individual, the method comprising administering to an individual a composition, wherein the composition comprises an

affinity ligand which selectively binds to a B cell determinant, wherein the B cells targeted by the method and by the composition are nonmalignant B cells, **[which]** wherein the composition is delivered into an access that directly supplies central nervous tissue undergoing demyelination, and wherein the composition is administered in an amount effective to deplete B cells.

7. **(Amended)** The method according to claim 6, wherein the nonmalignant B cells are B cells selected from the group consisting of mature B cells and memory B cells, CD19<sup>+</sup>[+]sTn<sup>+</sup>[+] B cells, CD19<sup>+</sup>[+]CD21<sup>+</sup>[+]sTn<sup>+</sup>[+] B cells, and CD19<sup>+</sup>[+]CD5<sup>+</sup>[+]sTn<sup>+</sup>[+] B cells, **[and]** or a combination thereof.
9. **(Amended)** The method according to claim 6, wherein the composition further comprises an additional component selected from the group consisting of one or more chemotherapeutic agents, an anti-inflammatory agent, a cytolytic agent, and a pharmaceutically acceptable carrier, **[and]** or a combination thereof.
10. **(Amended)** A method for reducing a pro-multiple sclerosis (pro-MS) immune response in an individual, the method comprising administering to an individual a composition, wherein the composition comprises an affinity ligand which selectively binds to a B cell determinant, wherein the B cells targeted by the method and by the composition are nonmalignant B cells, wherein the composition is administered intravenously, and wherein the composition is administered in an amount effective to deplete B cells.
11. **(Amended)** The method according to claim 10, wherein the nonmalignant B cells are B cells selected from the group consisting of mature B cells and memory B cells, CD10<sup>+</sup>[+] sTn<sup>+</sup>[+] B cells, CD19<sup>+</sup>[+] CD21<sup>+</sup>[+] sTn<sup>+</sup>[+] B cells, and CD19<sup>+</sup>[+] CD5<sup>+</sup>[+] sTn<sup>+</sup>[+] B cells, **[and]** or a combination thereof.

13. **(Amended)** The method according to claim 10, wherein the composition further comprises an additional component selected from the group consisting of one or ore chemotherapeutic agents, an anti-inflammatory agent, a cytolytic agent, **and** a pharmaceutically acceptable carrier, **[and] or** a combination thereof.
14. **(Amended)** A method for treating an individual having **[a disease condition selected from the group consisting of]** multiple sclerosis (MS) and a pro-MS immune response, **or having [and]** a pro-MS immune response, **the method comprising administering to an individual a composition,** wherein the composition comprises an affinity ligand which selectively binds to a B cell determinant, wherein the B cells targeted by the method and by the composition are nonmalignant B cells, and wherein the composition is administered in an amount to effect a reduction in inflammation underlying clinical manifestations of MS.
15. **(Amended)** The method according to claim 14, wherein the nonmalignant B cells are B cells selected from the group consisting of mature B cells and memory B cells, CD19<sup>+</sup>[+]sTn<sup>+</sup>[+] B cells, CD19<sup>+</sup>[+]CD21<sup>+</sup>[+]sTn<sup>+</sup>[+] B cells, **and** CD19<sup>+</sup>[+]CD5<sup>+</sup>[+]sTn<sup>+</sup>[+] B cells, **[and] or** a combination thereof.
17. **(Amended)** The method according to claim 14, wherein the composition further comprises an additional component selected from the group consisting of one or more chemotherapeutic agents, an anti-inflammatory agent, a cytolytic agent, **and** a pharmaceutically acceptable carrier, **[and] or** a combination thereof.